An experimental drug from Cytokinetics (CYTK) failed to improve the lung function of patients with ALS compared to a placebo. The company presented the negative outcome from a mid-stage clinical trial at a neurology conference on Sunday.

This is the second setback for Cytokinetics and its efforts to develop an effective treatment for ALS, a degenerative nerve disorder that is almost always fatal, typically from respiratory failure.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy